1109. Valgancyclovir Dosing for Cytomegalovirus Prophylaxis in Heart Transplant Recipients

BACKGROUND: Cytomegalovirus (CMV) is one of the most common infections after transplantation and continues to cause significant morbidity and mortality. Current guidelines recommend 3-6 months of post-transplant prophylaxis with 900mg daily of valganciclovir in heart transplant recipients. At our in...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Glen, Davis, Matthew R, Beaird, Omer E, Carlson, Margrit, Gaynor, Pryce, Multani, Ashrit, Deng, Mario, Nsair, Ali, Schaenman, Joanna M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776552/
http://dx.doi.org/10.1093/ofid/ofaa439.1295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776552/
http://dx.doi.org/10.1093/ofid/ofaa439.1295

Ejemplares similares